Recently, Wu (23) observed that the T790 mutation showed low consistency between cerebrospinal fluid (CSF) and plasma in the study of CSF genotyping in EGFR-mutated NSCLC, which could explain the poor response to Osimertinib in patients with T790 mutations detected in plasma. Here, EGFR is linked to non-small cell lung carcinoma.